Publication:
Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.

dc.contributor.authorEsteve-Pastor, María Asunción
dc.contributor.authorRivera-Caravaca, José Miguel
dc.contributor.authorRoldán-Rabadán, Inmaculada
dc.contributor.authorRoldán, Vanessa
dc.contributor.authorMuñiz, Javier
dc.contributor.authorRaña-Míguez, Paula
dc.contributor.authorRuiz-Ortiz, Martín
dc.contributor.authorCequier, Ángel
dc.contributor.authorBertomeu-Martínez, Vicente
dc.contributor.authorBadimón, Lina
dc.contributor.authorAnguita, Manuel
dc.contributor.authorLip, Gregory Y H
dc.contributor.authorMarín, Francisco
dc.contributor.authorFANTASIIA Investigators
dc.date.accessioned2023-01-25T10:01:13Z
dc.date.available2023-01-25T10:01:13Z
dc.date.issued2018
dc.description.abstractThe efficacy and safety of oral anticoagulation (OAC) using the vitamin K antagonists (VKA) are closely associated with the quality of anticoagulation, reflected by time in therapeutic range (TTR). The SAMe-TT2R2 is a risk score developed to predict the quality of anticoagulation control among VKA users. To analyse the quality of anticoagulation and its clinical determinants based on different methods in a prospective cohort of atrial fibrillation patients on VKA treatment participating in the multicentre Spanish observational registry FANTASIIA. Estimated TTR was calculated from Rosendaal, direct method, international normalized ratio variability, and NICE criteria. Time in therapeutic range values were compared for those patients with a SAMe-TT2R2 score 0-2 and >2. One thousand four hundred and seventy patients were analysed (56.4% male, mean age 74.1 ± 9.5 years). Mean TTR was 61.5 ± 25.1 with Rosendaal and 64.7 ± 24.2 with direct method. There was a high correlation between both methods (ρ = 0.805). The prevalence of poor anticoagulation control was 55%. Diabetes mellitus [odds ratio (OR) 1.38; P = 0.008], peripheral artery disease (PAD, OR 1.62; P = 0.048), and HAS-BLED (OR 1.13; P = 0.022) were independently associated with TTR 2. One thousand four hundred and seventy patients were analysed (56.4% male, mean age 74.1 ± 9.5 years). Mean TTR was 61.5 ± 25.1 with Rosendaal and 64.7 ± 24.2 with direct method. There was a high correlation between both methods (ρ = 0.805). The prevalence of poor anticoagulation control was 55%. Diabetes mellitus [odds ratio (OR) 1.38; P = 0.008], peripheral artery disease (PAD, OR 1.62; P = 0.048), and HAS-BLED (OR 1.13; P = 0.022) were independently associated with TTR 2 (P = 0.044), with a specificity of > 90% for predicting TTR  90% for predicting TTR  In a multicentre prospective registry, 55% of AF patients had poor anticoagulation control with diabetes mellitus, PAD, and HAS-BLED being independently associated with TTR 
dc.identifier.doi10.1093/europace/eux314
dc.identifier.essn1532-2092
dc.identifier.pmid29095971
dc.identifier.unpaywallURLhttps://academic.oup.com/europace/article-pdf/20/9/1435/25681779/eux314.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11762
dc.issue.number9
dc.journal.titleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
dc.journal.titleabbreviationEuropace
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.page.number1435-1441
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.rights.accessRightsopen access
dc.subject.meshAcenocoumarol
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnticoagulants
dc.subject.meshAtrial Fibrillation
dc.subject.meshComorbidity
dc.subject.meshDiabetes Mellitus
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInternational Normalized Ratio
dc.subject.meshMale
dc.subject.meshOdds Ratio
dc.subject.meshPeripheral Arterial Disease
dc.subject.meshPrevalence
dc.subject.meshProspective Studies
dc.subject.meshRegistries
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.subject.meshStroke
dc.subject.meshVitamin K
dc.titleQuality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number20
dspace.entity.typePublication

Files